COMP <GO>
INFU vs PROF // RSI-14 & 200D SMA MOMENTUM
InfuSystems Holdings Inc. (NYSE) VS. Profound Medical Corp. (NASDAQ) • 15-METRIC TALLY: INFU 6
— PROF 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: PROF
LAST: $13.84 (-1.63%) • MKT CAP: $280.2M
rsi-technicals
56.3
LAST: $6.73 (+2.44%) • MKT CAP: $240.0M
rsi-technicals
56.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INFU VS. PROF)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INFU | PROF | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.00% | 70.80% | -14.80 | PROF | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | -35.00% | +47.80 | INFU | /roic <GO> |
| EV/EBITDA & P/E Valuation | 24.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 8.29% | -17.93% | +26.22 | INFU | /fcf-yield <GO> |
| Operating Margin | 8.30% | -60.00% | +68.30 | INFU | /operating-margins <GO> |
| Net Profit Margin | 4.60% | -60.00% | +64.60 | INFU | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 65.30% | -58.90 | PROF | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.16 | 5.97 | -0.81 | PROF | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | INFU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 56.3 | 56.4 | -0.10 | PROF | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 40.4x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $280.2M | $240.0M | $40.2M | INFU | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INFU REV | PROF REV | INFU GROSS % | PROF GROSS % | INFU FCF | PROF FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $143.4M | $16.1M | 56.0% | 70.8% | $23.8M | -$38.4M |
| FY 2024 | $134.9M | $9.7M | 52.2% | 72.2% | $19.4M | -$23.5M |
| FY 2023 | $125.8M | $5.9M | — | — | $11.2M | -$22.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INFU // BETA —
PROF // BETA —